Summit Therapeutics Inc. Capital Expenditures Incurred but Not yet Paid
Summit Therapeutics Inc. (SMMT) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-23
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$746.00K, a 1136.11% decline year-over-year.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $746.00K.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $127.00K.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $92.00K.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $291.00K.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $0.00 10-Q · filed 2026-07-23 | $127.00K derived: sum of 3 quarters · filed 2026-07-23 | $219.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $746.00K 10-Q · filed 2026-04-30 | $873.00K derived: sum of 2 quarters · filed 2026-04-30 | $965.00K derived: sum of 3 quarters · filed 2026-04-30 | $1.04M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $127.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $219.00K derived: sum of 2 quarters · filed 2026-02-23 | $291.00K derived: sum of 3 quarters · filed 2026-07-23 | $291.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $164.00K derived: sum of 2 quarters · filed 2026-07-23 | $164.00K 10-Q · filed 2025-10-20 | $164.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $72.00K 10-Q · filed 2026-07-23 | $72.00K derived: sum of 3 quarters · filed 2026-07-23 | $72.00K derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | $0.00 10-Q · filed 2025-10-20 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |